Kurokohchi K, Akatsuka T, Pendleton C D, Takamizawa A, Nishioka M, Battegay M, Feinstone S M, Berzofsky J A
Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Virol. 1996 Jan;70(1):232-40. doi: 10.1128/JVI.70.1.232-240.1996.
To define cytotoxic T-cell (CTL) epitopes, the common approach involving the use of a series of overlapping synthetic peptides covering the whole protein sequence is impractical for large proteins. Motifs identify only a fraction of epitopes. To identify human CTL epitopes in the NS3 region of hepatitis C virus (HCV), we modified an approach using recombinant protein and the ability of short peptides to bind to class I major histocompatibility complex (MHC) molecules. Peripheral blood mononuclear cells from an HCV-infected patient were stimulated with a proteolytic digest of the recombinant NS3 protein to expand CTL to any active peptides in the digest. The digest was fractionated by reverse-phase high-performance liquid chromatography, and fractions were assessed for the ability to sensitize targets for lysis by CTL. The most active fraction was sequenced, identifying a 15-residue peptide (NS3-1J; TITTGAPVTYSTYGK). This sequence was confirmed to be the source of the activity by synthesis of the corresponding peptide. CTL lines specific for NS3-1J were established from two HCV-infected patients (both HLA-A2 and -B7 positive) by stimulation with the synthetic peptide in vitro. The CTL were HLA-A2 restricted, and the minimal epitope was mapped to a decapeptide NS3-1J (10.4). As this minimal epitope lacks the common HLA-A2-binding motif, this technique is useful for mapping CTL epitopes independent of known motifs and without the requirement for enormous numbers of overlapping peptides. Because this peptide is presented by the most common HLA class I molecule, present in almost half the population, it might be a useful component of a vaccine against HCV.
为了确定细胞毒性T细胞(CTL)表位,常用的方法是使用一系列覆盖整个蛋白质序列的重叠合成肽,但对于大蛋白来说这种方法并不实用。基序只能识别一部分表位。为了在丙型肝炎病毒(HCV)的NS3区域鉴定人CTL表位,我们改进了一种方法,利用重组蛋白以及短肽与I类主要组织相容性复合体(MHC)分子结合的能力。用重组NS3蛋白的蛋白水解消化物刺激一名HCV感染患者的外周血单核细胞,以扩增CTL至消化物中的任何活性肽。通过反相高效液相色谱对消化物进行分级分离,并评估各组分使靶细胞被CTL裂解的致敏能力。对活性最高的组分进行测序,鉴定出一个15个残基的肽段(NS3-1J;TITTGAPVTYSTYGK)。通过合成相应肽段证实该序列是活性来源。通过在体外用人合成肽刺激,从两名HCV感染患者(均为HLA-A2和-B7阳性)中建立了对NS3-1J特异的CTL系。这些CTL受HLA-A2限制,最小表位定位到一个十肽NS3-1J(10.4)。由于这个最小表位缺乏常见的HLA-A2结合基序,该技术可用于独立于已知基序且无需大量重叠肽来定位CTL表位。因为这个肽段由最常见的I类HLA分子呈递,几乎存在于一半的人群中,它可能是抗HCV疫苗的一个有用成分。